Article info
PDFLetter
Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis
- Correspondence to Professor Dimitrios Mougiakakos; dimitrios.mougiakakos{at}med.ovgu.de; Professor Aiden Haghikia; aiden.haghikia{at}med.ovgu.de
Citation
Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis
Publication history
- Received April 24, 2024
- Accepted June 18, 2024
- First published June 27, 2024.
Online issue publication
October 21, 2024
Article Versions
- Previous version (27 June 2024).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR.